课题基金 / 基金详情

Inhibiting tegumental carbonic anhydrase as a novel treatment for schistosomiasis

Inhibiting tegumental carbonic anhydrase as a novel treatment for schistosomiasis
抑制皮膜碳酸酐酶作为血吸虫病的新治疗方法
批准号:
8682118
负责人:
Patrick J Skelly
金额:
$20.54万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-03 至 2016-06-30

项目摘要

项目成果

Patrick J Skelly的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Schistosomiasis is a serious global health problem caused by intravascular parasitic worms called schistosomes. Currently ~200 million people are infected with these parasites. Tens of millions of people have chronic morbidity and new treatments are needed. We have identified a carbonic anhydrase enzyme (SmCA) that is an accessible and rational target of such treatment. The enzyme is expressed on the surface of intravascular stage schistosomes. Parasites with diminished SmCA (achieved through RNAi) fail to establish a robust infection in mice. Chemical compounds that mimic the RNAi effect and inhibit SmCA should likewise debilitate the worms. Carbonic anhydrases (CAs) are extremely druggable proteins and several drugs that target vertebrate CA isoforms are currently used to treat a number of conditions in humans. The aim of this application is to identify potent and specific SmCA inhibitors to test the hypothesis that these can form the basis for a novel anti-schistosome therapy. We partner here with Dr. Claudiu Supuran, a world leader in carbonic anhydrases and their inhibitors. Dr. Supuran has amassed a defined, unique set of ~400 CA inhibitors and chemical variants for testing here with SmCA. To facilitate testing, we have expressed SmCA as a secreted recombinant protein in a mammalian expression system and we have purified the active enzyme from the medium. Potent SmCA inhibitors identified by Dr. Supuran will be subject to a validated secondary screen in which their ability to decrease CA activity in living parasites in vitro is measured. Here, we will test all 3 major species of human schistosome to identify pan-schistosome CA inhibitors. We believe that our approach will yield effective schistosome CA inhibitors that will debilitate the parasites and form the basis of a new and urgently needed therapy to treat schistosomiasis, a neglected, global condition that remains a source of tremendous death and morbidity in the 21st century.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gene silencing in schistosomes using RNAi
  • 批准号:
    6871277
  • 项目类别:
  • 资助金额:
    $39.63万
  • 财政年份:
    2004
  • 负责人:
    Patrick J Skelly
  • 依托单位:
Functional Characterization of the Schistosome Tegument
  • 批准号:
    8964247
  • 项目类别:
  • 资助金额:
    $41.25万
  • 财政年份:
    2004
  • 负责人:
    Patrick J Skelly
  • 依托单位:
Functional Characterization of the Schistosome Tegument
  • 批准号:
    7986907
  • 项目类别:
  • 资助金额:
    $41.25万
  • 财政年份:
    2004
  • 负责人:
    Patrick J Skelly
  • 依托单位:
Gene silencing in schistosomes using RNAi
  • 批准号:
    7195716
  • 项目类别:
  • 资助金额:
    $37.57万
  • 财政年份:
    2004
  • 负责人:
    Patrick J Skelly
  • 依托单位:
海外基金